Takeaway

• High-dose ifosfamide was more effective at prolonging survival in recurrent and primary refractory Ewing sarcoma (RR-ES) compared to topotecan+cyclophosphamide, despite more discontinuations due to toxicities.
•  Before this trial, it was not possible to identify the most effective or most toxic regimen.

Why this matters

• 5-year survival for RR-ES...